[admin]

Understanding CA125 Testing and Its Role in Ovarian Cancer Management

For clinicians and laboratory professionals searching for reliable information on Carbohydrate Antigen 125 (CA125) testing, the key question is not simply "what does this marker measure," but "how reliable is it, and what supports its clinical use." Poclight, through its Tumor Marker product line, positions CA125 (Cancer Antigen 125) as an ovarian cancer marker used for recurrence monitoring and, when paired with complementary markers, for early detection. This article examines CA125’s clinical positioning, its known limitations, and how Poclight’s combined detection approach addresses those gaps.

What CA125 Is Used For

CA125 is classified within Poclight’s serum tumor marker line as a marker for ovarian cancer, serving two primary functions: monitoring disease recurrence after treatment and supporting early detection efforts when used alongside other markers. Tumor markers of this type—most of which are proteins—are generally applied across cancer management to track disease progression, assess treatment response, and detect recurrence following treatment.

The Core Limitation: Why CA125 Alone Is Not Sufficient

The central pain point associated with CA125 testing is its uneven sensitivity across disease stages. According to Poclight’s technical documentation, CA125 is elevated in 80% of advanced ovarian cancer cases but only 50% of early-stage cases. This gap means that relying on CA125 in isolation limits its usefulness for early detection, even though it remains informative for monitoring recurrence in patients with an established diagnosis.

The Combined Detection Solution: CA125 + HE4

To address this limitation, Poclight offers the Ovarian Cancer Combined Detection Panel, which pairs CA125 with HE4. This panel is directly positioned to improve early detection and recurrence monitoring where CA125 alone falls short.

The differentiated value of this combination centers on the ROMA index: combining CA125 with HE4 improves specificity to 95% through this calculation method. Beyond the ROMA index, the combined panel demonstrates the following documented performance:

• Sensitivity: 76–94%
• Specificity: 75–95%
• Accuracy: 93.8%

These figures reflect a meaningful improvement over the single-marker limitation noted earlier—where CA125 alone detects only half of early-stage cases. By adding HE4 to the panel, the combined approach is designed to compensate for that individual marker weakness, consistent with Poclight’s broader philosophy for its Clinical Combined Detection Solutions line: panels that compensate for individual marker limitations and improve sensitivity and specificity for specific cancer types.

Key Features of the Ovarian Cancer Combined Detection Panel

Summarizing the documented features of this panel:

• Markers used: CA125 + HE4
• Sensitivity range: 76–94%
• Specificity range: 75–95%
• Accuracy: 93.8%
• Clinical utility: Supports early detection and ongoing recurrence monitoring

This panel is adapted for use within Gynecology and Oncology Department settings, aligning with the clinical environments where ovarian cancer is typically diagnosed and followed over time.

How CA125 Fits Within Poclight’s Broader Tumor Marker Portfolio

CA125 does not operate in isolation within Poclight’s product matrix—it also appears in other combined panels designed for different cancer types. For example, the NSCLC Adenocarcinoma Combined Detection Panel incorporates CEA, CYFRA21-1, and CA125 together to help detect early-stage non-small cell lung cancer adenocarcinoma, achieving a sensitivity of 75% and specificity of 70%. Similarly, the Pancreatic Cancer Combined Detection Panel combines CEA, CA19-9, and CA125 to raise sensitivity to 82% and assist in predicting resectability.

This cross-panel use of CA125 illustrates a broader theme in Poclight’s product philosophy: individual markers such as tPSA, fPSA, and CEA are each positioned for specific cancer types—prostate cancer screening, prostate cancer gray-zone refinement, and pan-cancer recurrence monitoring respectively—while combined panels borrow and recombine these markers to address the specific diagnostic challenges of each cancer type. CA125’s role within both the ovarian-specific panel and these cross-cancer panels reflects this strategy of targeted recombination rather than reliance on any single marker.

The Technology Behind the Testing: C5000 Dry Micro System

Poclight’s CA125 and HE4 testing, along with its other serum tumor marker tests, are supported by the C5000 Dry Micro System, a semi-automatic, portable diagnostic platform. This system is built on dry micro reagent format technology, using lyophilized and liquid complementary reagents, with wash-free separation that requires no magnetic beads and no complex liquid path.

From a technical performance standpoint, the C5000 system delivers:

• First sample result: 3 minutes
• Channel capacity: 7-channel
• Accuracy: CV < 5% (with CV < 3% noted specifically for the C5000 system itself)
• Throughput: 80 tests/hour
• Weight: ≤ 8.5 kg

The platform also supports touch screen operation and LIS/HIS transmission, enabling real-time information sharing within hospital information systems. This combination of rapid turnaround, simple operation, and low-maintenance reagent handling directly addresses the pain points of laboratories and clinical departments that need quick, dependable results without complex instrumentation.

Clinical Consensus Supporting Combined Marker Testing

While the specific CA125 + HE4 combination is Poclight’s own documented panel, the broader rationale for combined marker testing in oncology is reinforced by clinical consensus statements referenced in Poclight’s materials. For instance, guidance on NSCLC testing notes that a single marker like CYFRA21-1 shows less positive correlation in prognosis alone, while combining markers helps distinguish early-stage disease from benign conditions. This same logic—that single markers have inherent limitations which combined panels are designed to offset—underlies the clinical rationale for the CA125 + HE4 approach to ovarian cancer.

Conclusion

CA125 testing remains a relevant tool for ovarian cancer recurrence monitoring, but its documented limitation—detecting only 50% of early-stage cases compared to 80% of advanced cases—means it performs best as part of a combined approach. Poclight’s Ovarian Cancer Combined Detection Panel, pairing CA125 with HE4 and supported by the ROMA index calculation, documents sensitivity of 76–94%, specificity of 75–95%, and accuracy of 93.8%. Delivered through the C5000 Dry Micro System’s rapid, low-complexity testing format, this combined panel reflects Poclight’s broader approach across its Tumor Marker portfolio: using markers like CA125, tPSA, fPSA, and CEA—individually and in combination—to match testing strategy to the specific clinical challenge of each cancer type, within Gynecology, Oncology Department, and related clinical settings.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts